JP2008530347A - 免疫刺激性ポリホスファゼン化合物 - Google Patents
免疫刺激性ポリホスファゼン化合物 Download PDFInfo
- Publication number
- JP2008530347A JP2008530347A JP2007556339A JP2007556339A JP2008530347A JP 2008530347 A JP2008530347 A JP 2008530347A JP 2007556339 A JP2007556339 A JP 2007556339A JP 2007556339 A JP2007556339 A JP 2007556339A JP 2008530347 A JP2008530347 A JP 2008530347A
- Authority
- JP
- Japan
- Prior art keywords
- polyphosphazene polymer
- antigen
- composition
- polyphosphazene
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002627 poly(phosphazenes) Polymers 0.000 title claims abstract description 79
- 150000001875 compounds Chemical class 0.000 title claims description 23
- 230000003308 immunostimulating effect Effects 0.000 title description 8
- 229920000642 polymer Polymers 0.000 claims abstract description 134
- 239000000427 antigen Substances 0.000 claims abstract description 69
- 102000036639 antigens Human genes 0.000 claims abstract description 69
- 108091007433 antigens Proteins 0.000 claims abstract description 69
- 239000000203 mixture Substances 0.000 claims description 28
- 230000028993 immune response Effects 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 17
- 241000282412 Homo Species 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000011859 microparticle Substances 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 12
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- JHAYEQICABJSTP-UHFFFAOYSA-N decoquinate Chemical group N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 claims 1
- 239000011882 ultra-fine particle Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 2
- 239000002671 adjuvant Substances 0.000 description 38
- 239000000178 monomer Substances 0.000 description 11
- 125000001931 aliphatic group Chemical group 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 150000001735 carboxylic acids Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229920003169 water-soluble polymer Polymers 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 150000002148 esters Chemical group 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001571 immunoadjuvant effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- -1 methoxyethoxyethoxy Chemical group 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 125000004437 phosphorous atom Chemical group 0.000 description 3
- 229920002632 poly(dichlorophosphazene) polymer Polymers 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007824 aliphatic compounds Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000002892 organic cations Chemical class 0.000 description 2
- 125000005429 oxyalkyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- VHUVBWVDIFVVBI-SNYZSRNZSA-N (2s)-3-(4-hydroxyphenyl)-2-(octadecylamino)propanoic acid;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCCCCCN[C@H](C(O)=O)CC1=CC=C(O)C=C1 VHUVBWVDIFVVBI-SNYZSRNZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- HSVDYEDYDOKETI-UHFFFAOYSA-N 1,2-dihydroxy-2-(hydroxymethyl)octadecan-3-one Chemical compound CCCCCCCCCCCCCCCC(=O)C(O)(CO)CO HSVDYEDYDOKETI-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- VJOWMORERYNYON-UHFFFAOYSA-N 5-ethenyl-2-methylpyridine Chemical compound CC1=CC=C(C=C)C=N1 VJOWMORERYNYON-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 0 CN=*(OCc(cc1)ccc1C(O)=O)OCc(cc1)ccc1C(O)=O Chemical compound CN=*(OCc(cc1)ccc1C(O)=O)OCc(cc1)ccc1C(O)=O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- TUTWLYPCGCUWQI-UHFFFAOYSA-N decanamide Chemical compound CCCCCCCCCC(N)=O TUTWLYPCGCUWQI-UHFFFAOYSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N noncarboxylic acid Natural products CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 239000012704 polymeric precursor Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
- C08G79/02—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing phosphorus
- C08G79/025—Polyphosphazenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
Description
脂肪族化合物;アリール;アラルキル;アルカリル;カルボン酸;複素環式芳香族化合物;グルコースを含む炭水化物;ヘテロアルキル;ハロゲン;アルキルアミノを含む脂肪族アミノ;ヘテロアラルキル;ジアルキルアミノ、アリルアミノ、ジアリルアミノ、アルキルアリルアミノを含む2価(脂肪族)アミノ;必ずしもそれに限定されないが、オキシフェニルCO2H、オキシフェニルSO3H、オキシフェニルヒドロキシル、およびオキシフェニルPO3Hを含むオキシアリル;オキシアルキル、オキシ(脂肪族)CO3H、オキシ脂肪族SO3H、オキシ(脂肪族)PO3Hを含むオキシ脂肪族、およびオキシ(アルキル)ヒドロキシルを含むオキシ(脂肪族)ヒドロキシル;オキシアルカリル;オキシアラルキル;チオアリル;チオアルキルを含むチオ脂肪族;チオアルカリル;チオアラルキル;−−NHC(O)O−(アリールまたは脂肪族);−−O−−[(CH3)xO]y−−CH2)−−O−−[(CH2)xO]y(CH2)xNH(CH2)xSO3H;および、−−O−−(CH2)xO]y−(アリールまたは脂肪族);ここで、xは1−8であり、yは1から20の整数である。これらの基は、例えば酸素、硫黄、窒素または炭素原子を通してリン原子に結合することができる。
であり、ここで、
であり、dは0から15である。
脂肪族化合物;アリール;アラルキル;アルカリル;カルボン酸;複素環式芳香族化合物;グルコースを含む炭水化物;ヘテロアルキル;ハロゲン;アルキルアミノを含む脂肪族アミノ;ヘテロアラルキル;ジアルキルアミノ、アリルアミノ、ジアリルアミノ、アルキルアリルアミノを含む2価(脂肪族)アミノ;必ずしもそれに限定されないが、オキシフェニルCO2H、オキシフェニルSO3H、オキシフェニルヒドロキシル、およびオキシフェニルPO3Hを含むオキシアリル;オキシアルキル、オキシ(脂肪族)CO2H、オキシ脂肪族SO3H、オキシ(脂肪族)PO3Hを含むオキシ脂肪族、およびオキシ(アルキル)ヒドロキシルを含むオキシ(脂肪族)ヒドロキシル;オキシアルカリル;オキシアラルキル;チオアリル;チオアルキルを含むチオ脂肪族;チオアルカリル;チオアラルキル;−−NHC(O)O−(アリールまたは脂肪族);−−O−−[(CH2)xO]y−−CH2)−−O−−[(CH2)xO]y(CH2)xNH(CH2)xSO3H;および、−−O−−(CH2)xO]y−(アリールまたは脂肪族);ここで、xは1−8であり、yは1から20の整数である。これらの基は、例えば酸素、硫黄、窒素または炭素原子を通してリン原子に結合することができる。
ジミリストイル・ホスファチジルコリン、臭化ジメチルジオクタデシルアンモニウム、N,N−ジオクタデシル−N’、N’−ビス(2−ヒドロキシエチル)プロパンジアミン、N−(2−デオキシ−2−L−ロイシルアミノ−β−D−グルコピラノシル)−N−オクタデシドデカノイルアミド・ヒドロ酢酸、ジミリストイル・ホスファチジルグリセロール、N−アセチルグルコサミニル−N−アセチルムラミル−L−Ala−D−イソGlu−L−Ala−グリセロールジパルミチン酸塩、三オレイン酸ソルビタン、デオキシコール酸ナトリウム塩、リン酸ジセチル、モノ−パルミトイル−rac−グリセロール、N−アセチルグルコサミニル−N−アセチルムラミル−L−Ala−D−イソGlu−L−Ala−ジパルミトキシ・プロピルアミド、オクタデシル・チロシン塩酸塩、D−ムラパルミチン、3−O−デスアシル−4’−モノホスホリル脂質A、mannide oleate、1a,25−ジヒドロキシビタミンD3、ホスファチジン酸、ホスファチジルエタノールアミン、ホスファチジルコリン、ホスファチジルセリン、ホスファチジルイノシトール、スフィンゴシン(D−4−スフィンゲニン、セラミデ、スフィンゴミエリン、ガラクシトシルセラミド、GM2(ガングリオシド)、オレイン酸、パルミチン酸、カプリン酸、ラウリン酸、ミリスチン酸、ステアリン酸、アラキジン酸、べヘン酸、リグノセリン酸、セロチン酸、リノール酸、リノレン酸、アラキドン酸などを含む脂肪酸塩。
ポリ{ジ[4−(2−カルボキシエチル)フェノキシ]ホスファゼン}の合成。
ポリマーは、実施例1で説明したとおりに合成された。ポリマー構造、試薬、試薬の量および反応状況を表1に示す。
実施例1(ポリマー1)および実施例2(ポリマー2)で説明したように合成されたポリマーを、B型肝炎表面抗原−HBsAg(バイオデザイン・インターナショナル製)に対する免疫応答(アジュバント活性)を促進する能力を測るため、in vivoで評価した。ここではBALB/cマウスを使用した(グループにつき5匹のマウス)。溶液(最終容量、100μl)中において50μgのポリマーと混合した1μgのHBsAgを各々のマウスに注入した。抗原だけを含む処方、50μgのPCPPにより処方された抗原およびアルミニウムアジュバントにより処方された抗原を対照として使用した。マウスは、一回の筋内注射により免疫化した。血液サンプルは、免疫化後16週で集められ、また血清は分析まで貯蔵された。
ポリマー1および2は実施例13で説明したのと同様にマウスにおいて評価した。ただし、実施例13と違い、5μgのX−31インフルエンザ(チャールズ・リバー研究所製)をHBsAgの代わりに使用した。
Claims (27)
- 請求項1に基づく少なくとも1個のポリホスファゼンポリマーと抗原を含むヒトまたは動物に免疫応答を誘導することを特徴とする組成物。
- 請求項11に基づくヒトまたは動物に免疫応答を誘導する組成物であって、前記抗原は、タンパク質、ペプチド、多糖類、糖タンパク質、糖脂質、核酸、およびこれらの組合せよりなるグループから選抜され、それらが細胞、細菌、ウイルス粒子、およびそれらの組合せより成るグループから誘導されることを特徴とする組成物。
- 請求項11に基づくヒトまたは動物に免疫応答を誘導する組成物であって、前記ポリホスファゼンポリマーおよび前記抗原が非共有結合水溶性複合体を形成することを特徴とする組成物。
- 請求項13に基づくヒトまたは動物に免疫応答を誘導する組成物であって、前記ポリホスファゼンポリマーおよび前記抗原が、多量体抗原提示が可能な非共有水溶性複合体を形成することを特徴とする組成物。
- 請求項11に基づくヒトまたは動物に免疫応答を誘導する組成物であって、前記抗原がポリホスファゼンポリマーに共有結合して接合されることを特徴とする組成物。
- 請求項11に基づくヒトまたは動物に免疫応答を誘導する組成物であって、前記ポリホスファゼンポリマーが極微粒子またはマイクロクロゲルを形成するために多価イオンとイオン架橋されることを特徴とする組成物。
- 請求項17に基づく少なくとも1個のポリホスファゼンポリマーおよび抗原を含むヒトまたは動物に免疫応答を誘導することを特徴とする組成物。
- 請求項22に基づくヒトまたは動物に免疫応答を誘導する組成物であって、前記抗原が、タンパク質、ペプチド、多糖類、糖タンパク質、糖脂質、核酸、およびそれらの組合せより成るグループから選択され、それらが細胞、細菌、ウイルス粒子、およびそれらの部分り成るグループから誘導されることを特徴とする組成物。
- 請求項22に基づくヒトまたは動物に免疫応答を誘導する組成物であって、前記ポリホスファゼンポリマーおよび抗原が非共有結合水溶性複合体を形成することを特徴とする組成物。
- 請求項24に基づくヒトまたは動物に免疫応答を誘導する組成物であって、前記ポリホスファゼンポリマーおよび前記抗原が、多量体抗原提示が可能な非共有水溶性複合体を形成することを特徴とする組成物。
- 請求項22に基づくヒトまたは動物に免疫応答を誘導する組成物であって、前記抗原が共有結合によりポリホスファゼンポリマー接合されることを特徴とする組成物。
- 請求項22に基づくヒトまたは動物に免疫応答を誘導する組成物であって、前記ポリホスファゼンポリマーが極微粒子またはマイクロクロゲルを形成するために多価イオンとイオン架橋されることを特徴とする組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65456705P | 2005-02-18 | 2005-02-18 | |
US60/654,567 | 2005-02-18 | ||
PCT/US2006/005736 WO2006089161A2 (en) | 2005-02-18 | 2006-02-17 | Immunostimulating polyphosphazene compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008530347A true JP2008530347A (ja) | 2008-08-07 |
JP5112081B2 JP5112081B2 (ja) | 2013-01-09 |
Family
ID=36917109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007556339A Expired - Fee Related JP5112081B2 (ja) | 2005-02-18 | 2006-02-17 | 免疫刺激性ポリホスファゼン化合物 |
Country Status (5)
Country | Link |
---|---|
US (6) | US20060193820A1 (ja) |
EP (1) | EP1858530B1 (ja) |
JP (1) | JP5112081B2 (ja) |
CA (1) | CA2642734A1 (ja) |
WO (1) | WO2006089161A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008536978A (ja) * | 2005-04-15 | 2008-09-11 | パラレル ソリューションズ,インク. | ピロリドン側基を含む生分解性ポリホスファゼン |
JP2009531471A (ja) * | 2006-01-18 | 2009-09-03 | 韓国科学技術研究院 | 生分解性及び温度感応性ポリ有機フォスファゼンの製造方法及び用途 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080166390A1 (en) * | 2006-04-11 | 2008-07-10 | Andrianov Alexander K | Biodegradable polyphosphazenes containing pyrrolidone side groups |
US20060193820A1 (en) * | 2005-02-18 | 2006-08-31 | Andrianov Alexander K | Immunostimulating polyphosphazene compounds |
CA2692740A1 (en) * | 2007-07-09 | 2009-01-15 | Apogee Technology, Inc. | Immunostimulating polyphosphazene compounds for intradermal immunization |
US20090016935A1 (en) * | 2007-07-09 | 2009-01-15 | Andrianov Alexander K | Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations |
US8685900B2 (en) * | 2009-04-03 | 2014-04-01 | Halliburton Energy Services, Inc. | Methods of using fluid loss additives comprising micro gels |
US11472927B2 (en) | 2015-11-18 | 2022-10-18 | University Of Maryland, College Park | Polyphosphazenes, methods of making, and uses thereof |
US11397282B1 (en) * | 2018-06-29 | 2022-07-26 | Hrl Laboratories, Llc | Infrared-transparent polymer optics and methods of making and using the same |
WO2023158805A1 (en) * | 2022-02-18 | 2023-08-24 | Georgia Tech Research Corporation | Lithiated polyphosphazene solid polymer electrolyte compositions and methods of manufacture thereof |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5891787A (ja) * | 1982-11-15 | 1983-05-31 | Moriroku Kk | 植物培地調整方法 |
JPS63162724A (ja) * | 1986-12-26 | 1988-07-06 | Otsuka Chem Co Ltd | スルホン基を有するオリゴエチレンオキシポリホスフアゼン及びその製法 |
JPS63186737A (ja) * | 1987-01-29 | 1988-08-02 | Teijin Ltd | 陰イオン固定型の高分子固体電解質 |
JPH02193999A (ja) * | 1989-01-20 | 1990-07-31 | Otsuka Chem Co Ltd | ポリホスフアゼン系電解質及びその用途 |
JPH03140330A (ja) * | 1989-10-27 | 1991-06-14 | Teijin Ltd | 生物学的活性物質固定体及びその製造方法並びにその製造用担体及びその使用方法 |
WO1998039386A1 (en) * | 1997-03-04 | 1998-09-11 | Avant Immunotherapeutics, Inc. | Recovery of polyphosphazene polyacids or acid salts thereof |
WO1998051740A2 (en) * | 1997-05-14 | 1998-11-19 | Virus Research Institute, Inc. | Purification of polyphosphazene polyacids |
JP2000516129A (ja) * | 1996-07-02 | 2000-12-05 | ヴァイラス リサーチ インスティチュート | コアセルベーションによるイオン架橋ポリホスファゼンマイクロスフェアの調製 |
JP2005528488A (ja) * | 2002-06-03 | 2005-09-22 | パラレル ソリューションズ,インコーポレイテッド | スルホン化ポリホスファゼン、その使用法、及びその調製法 |
JP2006528718A (ja) * | 2003-07-25 | 2006-12-21 | コリア インスティテュート オブ サイエンス アンド テクノロジー | 温度感応性ポリホスファゼン系高分子、その製造方法、及びそれを用いた注入型温度感応性ポリホスファゼンヒドロゲル |
JP2008536978A (ja) * | 2005-04-15 | 2008-09-11 | パラレル ソリューションズ,インク. | ピロリドン側基を含む生分解性ポリホスファゼン |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4258173A (en) | 1978-09-08 | 1981-03-24 | The Firestone Tire & Rubber Company | Polyphosphazene polymers containing monoetheroxy and polyetheroxy substituents |
US4640849A (en) * | 1986-01-31 | 1987-02-03 | Loctite (Ireland) Limited | Meta-bridged styryloxy resins |
US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
US5562909A (en) * | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
US5855895A (en) * | 1995-06-07 | 1999-01-05 | Virus Research Institute | Polyphosphazene polyelectrolyte immunoadjuvants |
US20040265326A1 (en) * | 1996-07-12 | 2004-12-30 | Cates George A. | Subunit respiratory syncytial virus vaccine preparation |
US5707597A (en) * | 1996-11-13 | 1998-01-13 | Virus Research Institute, Inc. | Polyhalophosphazene solutions stable against gelation |
US5869016A (en) * | 1997-06-18 | 1999-02-09 | Virus Research Institute, Inc. | Production of polyorganophosphazenes having desired molecular weights |
US5958414A (en) | 1997-09-03 | 1999-09-28 | Heska Corporation | Composition to protect a mammal against Bartonella henselae infection |
DE69932717T2 (de) * | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | Methoden und produkte zur induzierung mukosaler immunität |
US6261573B1 (en) * | 1998-10-30 | 2001-07-17 | Avant Immunotherapeutics, Inc. | Immunoadjuvants |
US20060193820A1 (en) * | 2005-02-18 | 2006-08-31 | Andrianov Alexander K | Immunostimulating polyphosphazene compounds |
-
2006
- 2006-02-16 US US11/355,737 patent/US20060193820A1/en not_active Abandoned
- 2006-02-17 WO PCT/US2006/005736 patent/WO2006089161A2/en active Application Filing
- 2006-02-17 CA CA002642734A patent/CA2642734A1/en not_active Abandoned
- 2006-02-17 JP JP2007556339A patent/JP5112081B2/ja not_active Expired - Fee Related
- 2006-02-17 EP EP06720860.3A patent/EP1858530B1/en not_active Not-in-force
-
2010
- 2010-08-24 US US12/806,941 patent/US20100322891A1/en not_active Abandoned
-
2013
- 2013-01-17 US US13/743,824 patent/US20130136758A1/en not_active Abandoned
-
2014
- 2014-07-03 US US14/323,083 patent/US20140314707A1/en not_active Abandoned
-
2015
- 2015-05-13 US US14/710,798 patent/US20150238600A1/en not_active Abandoned
- 2015-12-22 US US14/977,848 patent/US9687546B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5891787A (ja) * | 1982-11-15 | 1983-05-31 | Moriroku Kk | 植物培地調整方法 |
JPS63162724A (ja) * | 1986-12-26 | 1988-07-06 | Otsuka Chem Co Ltd | スルホン基を有するオリゴエチレンオキシポリホスフアゼン及びその製法 |
JPS63186737A (ja) * | 1987-01-29 | 1988-08-02 | Teijin Ltd | 陰イオン固定型の高分子固体電解質 |
JPH02193999A (ja) * | 1989-01-20 | 1990-07-31 | Otsuka Chem Co Ltd | ポリホスフアゼン系電解質及びその用途 |
JPH03140330A (ja) * | 1989-10-27 | 1991-06-14 | Teijin Ltd | 生物学的活性物質固定体及びその製造方法並びにその製造用担体及びその使用方法 |
JP2000516129A (ja) * | 1996-07-02 | 2000-12-05 | ヴァイラス リサーチ インスティチュート | コアセルベーションによるイオン架橋ポリホスファゼンマイクロスフェアの調製 |
WO1998039386A1 (en) * | 1997-03-04 | 1998-09-11 | Avant Immunotherapeutics, Inc. | Recovery of polyphosphazene polyacids or acid salts thereof |
WO1998051740A2 (en) * | 1997-05-14 | 1998-11-19 | Virus Research Institute, Inc. | Purification of polyphosphazene polyacids |
JP2005528488A (ja) * | 2002-06-03 | 2005-09-22 | パラレル ソリューションズ,インコーポレイテッド | スルホン化ポリホスファゼン、その使用法、及びその調製法 |
JP2006528718A (ja) * | 2003-07-25 | 2006-12-21 | コリア インスティテュート オブ サイエンス アンド テクノロジー | 温度感応性ポリホスファゼン系高分子、その製造方法、及びそれを用いた注入型温度感応性ポリホスファゼンヒドロゲル |
JP2008536978A (ja) * | 2005-04-15 | 2008-09-11 | パラレル ソリューションズ,インク. | ピロリドン側基を含む生分解性ポリホスファゼン |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008536978A (ja) * | 2005-04-15 | 2008-09-11 | パラレル ソリューションズ,インク. | ピロリドン側基を含む生分解性ポリホスファゼン |
JP2009531471A (ja) * | 2006-01-18 | 2009-09-03 | 韓国科学技術研究院 | 生分解性及び温度感応性ポリ有機フォスファゼンの製造方法及び用途 |
US9526699B2 (en) | 2006-01-18 | 2016-12-27 | Kist | Biodegradable and thermosensitive poly(organophosphazene) hydrogel, preparation method thereof and use thereof |
Also Published As
Publication number | Publication date |
---|---|
US20100322891A1 (en) | 2010-12-23 |
EP1858530A4 (en) | 2008-07-02 |
WO2006089161A3 (en) | 2007-05-31 |
CA2642734A1 (en) | 2006-08-24 |
US20150238600A1 (en) | 2015-08-27 |
EP1858530A2 (en) | 2007-11-28 |
US20060193820A1 (en) | 2006-08-31 |
US20160106833A1 (en) | 2016-04-21 |
US20140314707A1 (en) | 2014-10-23 |
US9687546B2 (en) | 2017-06-27 |
US20130136758A1 (en) | 2013-05-30 |
WO2006089161A2 (en) | 2006-08-24 |
JP5112081B2 (ja) | 2013-01-09 |
EP1858530B1 (en) | 2018-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5112081B2 (ja) | 免疫刺激性ポリホスファゼン化合物 | |
AU691824B2 (en) | Phosphazene polyelectrolytes as immunoadjuvants | |
Dmour et al. | Recent advances on chitosan as an adjuvant for vaccine delivery | |
JP3242118B2 (ja) | 生体内分解性標的指向性マイクロパーティクル送達システム | |
JP5344558B2 (ja) | カチオン性ナノゲルを用いる粘膜ワクチン | |
AU690567B2 (en) | Hydrogel microencapsulated vaccines | |
US5855895A (en) | Polyphosphazene polyelectrolyte immunoadjuvants | |
JP6228967B2 (ja) | 抗原性組成物および方法 | |
CN105188744A (zh) | 基于纳米颗粒的组合物 | |
CN108368260B (zh) | 含有角鲨烯的基于两亲性聚氨基酸聚合物的疫苗佐剂组合物 | |
US20170258900A1 (en) | Immunostimulating Polyphosphazene Compounds | |
WO2001015727A2 (en) | Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof | |
Rosales-Mendoza et al. | Silica-based mucosal nanovaccines | |
WO2023032891A1 (ja) | 免疫原性増強用組成物 | |
AU738698B2 (en) | Polyphosphazene polyelectrolyte immunoadjuvants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090217 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111019 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111025 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120224 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120302 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120323 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120423 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120911 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121010 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151019 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5112081 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |